OCT 29, 2021 11:00 AM PDT

Common Antidepressant Reduces COVID-19 Hospitalizations by 30%

WRITTEN BY: Annie Lennon

The widely-available antidepressant fluvoxamine reduces COVID-19 hospitalizations by 30%. The corresponding study was published in The Lancet Global Health

Fluvoxamine has a well-known safety profile and has been used as an antidepressant since the 1990’s for various conditions. Due to its anti-inflammatory properties, scientists had suspected since the beginning of the pandemic that it may have utility in treating the cytokine storms, an excessive and deadly immune response that presents in severe cases of COVID-19. 

In 2020, a study was published by researchers from the Washington University School of Medicine concerning the drug. In a placebo-controlled trial involving 152 patients with COVID-19, they found that patients taking fluoxetine ‘did not develop serious breathing difficulties or require hospitalization for problems with lung function’.  

The present study echoes and expands on these results. Under placebo-controlled, randomized conditions, the researchers split 1497 patients with COVID-19 into two treatment arms: one receiving 100 mg of fluvoxamine twice daily for 10 days or a placebo. 

The average age of participants was 50 years old, and 58% were female. All were at a high risk of developing severe symptoms of the disease. Both groups were tracked for 28 days following the trial to determine the effect of the drug. 

The researchers found that patients receiving fluvoxamine were hospitalized 30% less than those taking placebos. They also note, however, that of the 741 patients receiving fluoxetine, 84 discontinued treatment due to intolerability, while 64 stopped taking the placebo also due to intolerability. 

“Fluvoxamine is, so far, the only treatment that if administered early, can prevent COVID-19 from becoming a life-threatening illness. It could be one of our most powerful weapons against the virus and its effectiveness is one of the most important discoveries we have made since the pandemic began,” said Edward Mills, professor of McMaster's Department of Health Research Methods, Evidence, and Impact and co-principal investigator for the TOGETHER Trial, a group of clinical trials aiming to test potential COVID-19 treatments in community settings.

He added that as fluvoxamine costs around $4 per 10-day course, it may be particularly beneficial for poorer countries with low rates of vaccination, and who lack access to other COVID-19 therapy options. 

 

Sources: The Lancet Global Health, LabRoots, News Medical

 

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
NOV 02, 2021
Coronavirus
COVID vaccines have saved 245,000 lives and counting
NOV 02, 2021
COVID vaccines have saved 245,000 lives and counting
What began in December 31, 2019 as a cluster of cases of pneumonia with an unknown etiology, quickly spread throughout t ...
NOV 08, 2021
Drug Discovery & Development
A case study of CBD's tumor shrinking potential
NOV 08, 2021
A case study of CBD's tumor shrinking potential
A recent article published in the British Medical Journal reported the case of a woman who shrank a tumor by taking CBD. ...
NOV 08, 2021
Coronavirus
Pfizer Claims Their New COVID-19 Pill Reduces Hospitalization Risk by 89%
NOV 08, 2021
Pfizer Claims Their New COVID-19 Pill Reduces Hospitalization Risk by 89%
Current treatments for COVID-19 have to be administered intravenously, so a pill that could treat patients would be huge ...
NOV 09, 2021
Microbiology
Can This Cat Parasite Become a Tumor Treatment?
NOV 09, 2021
Can This Cat Parasite Become a Tumor Treatment?
You may have heard of Toxoplasma gondii because it is so common. Cats carry this parasite, and anyone that cleans a litt ...
NOV 29, 2021
Genetics & Genomics
A CRISPR-Based Technique to Make New Antibiotics
NOV 29, 2021
A CRISPR-Based Technique to Make New Antibiotics
There are many bacterial organisms, and they can live cooperatively, or they can battle one another. They are also capab ...
DEC 06, 2021
Microbiology
Sino Biological Launched Omicron Variant Research Reagents
DEC 06, 2021
Sino Biological Launched Omicron Variant Research Reagents
Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529) Beijing, China, D ...
Loading Comments...